Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

Bando, Hideaki; Kagawa, Yutaka; Kato, Takeshi; Akagi, Kiwamu; Denda, Tadamichi; Nishina, Tomohiro; Komatsu, Yoshito; Oki, Eiji; Kudo, Toshihiro; Kumamoto, Hiroshi; Yamanaka, T.; Yoshino, Takayuki

doi:10.1038/s41416-020-0766-1

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 45 GO enrichment and KEGG pathway analyses further revealed that the hub lncRNAs were involved in the RAS signaling pathway and transcriptional activator activity, as reported in previous studies. 46–48 In vivo and in vitro assays were conducted to verify if overexpression of LINC00909 could enhance NCRT resistance in CRC, and were consistent with the microarray and qPCR results.…”

Section: Discussionmentioning

confidence: 57%

LncRNAs Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer

Zhang

Guan

et al. 2021

JIR

View full text Add to dashboard Cite

Background There are only limited studies on the long non-coding RNAs (lncRNAs) associated with neoadjuvant chemoradiotherapy (NCRT) response and prognosis of locally advanced rectal cancer (LARC) patients. This study identified lncRNAs associated with NCRT response and prognosis in CRC patients and explored their potential predictive mechanisms. Methods The study subjected the LncRNA expression profiles from our previous gene chip data to LASSO and identified a four-lncRNA signature that predicted NCRT response and prognosis. A Cox regression model was subsequently performed to identify the prognostic risk factors. The function of LINC00909, the lncRNA with the most powerful predictive ability, was finally identified in vivo and in vitro using CRC cell lines. Results A comparison of the relative lncRNA expression of NCRT-responsive and non-responsive patients revealed four hub lncRNAs: DBET, LINC00909, FLJ33534, and HSD52 with AUC = 0.68, 0.73, 0.73, and 0.70, respectively (all p < 0.05). COX regression analysis further demonstrated that DBET, LINC00909 and FLJ33534 were associated with the DFS in CRC patients. The expression of the four lncRNAs was also significant in LARC patients who had not undergone NCRT (all p < 0.05). A risk score model was subsequently constructed based on the results of the multivariate COX analysis and used to predict NCRT response and prognosis in the CRC and LARC patients. The expression and prognosis of DBET, LINC00909 and FLJ33534 in the CRC tissues were further validated in the R2 platform and Oncomine database. Notably, overexpression of the LINC00909 increased the cell line resistance to the 5-FU and radiotherapy in vivo and in vitro. Conclusion DBET, LINC00909, and FLJ33534 are potential novel biomarkers for predicting NCRT response and prognosis in CRC patients. In particular, LINC00909 is an effective oncogene in CRC that could be used as a novel therapeutic target to enhance NCRT response.

show abstract

Section: Discussionmentioning

confidence: 57%

LncRNAs Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer

Zhang

Guan

et al. 2021

JIR

View full text Add to dashboard Cite

show abstract

“…The ceRNA network was constructed based on the hypothesis that lncRNAs directly interact with miRNAs and regulate the activity of mRNAs by acting as miRNA sponges [41]. Based on the associated mRNA, the GO enrichment and KEGG analysis were performed, the results demonstrated that the hub lncRNAs involve in the RAS signaling pathway and transcriptional activator activity, which had been reported in the previous studies [42][43][44]. Moreover, we successfully constructed the LINC00909 overexpression CRC cell lines to veri ed that overexpression LINC00909 could enhance the resistance to the NCRT in CRC.…”

Section: Discussionmentioning

confidence: 68%

LncRNAs Signature Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer

Zhang¹,

Guan²,

Wu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background Long non-coding RNAs (lncRNAs) are promising diagnostic and prognostic biomarkers in cancers. Neoadjuvant chemoradiotherapy (NCRT) is the standard of care for patients with locally advanced rectal cancer (LARC). However, studies are limited regarding lncRNAs associated NCRT response and prognosis of LARC patients. This study aimed to identify lncRNAs associated with NCRT response and prognosis in CRC patients, and to explore potential mechanisms. Methods LncRNA expression profiles from our previous gene chip data basing on the LASSO to identify a four-lncRNA signature that predicted NCRT response and prognosis and further validated in 138 colorectal cancer (CRC) patients and 36 LARC patients from our center. A Cox regression model was performed to identify prognostic risk factors. Moreover, we identified the function of the LINC00909 in vivo and in vitro in CRC cell lines. Results Four hub lncRNAs (DBET, LINC00909, FLJ33534, and HSD52) were screened by comparing the relative lncRNA expression of NCRT-responsive and non-responsive patients (AUC = 0.68, 0.73, 0.73, and 0.70, respectively, all p < 0.05). A competing endogenous RNA (ceRNA) network was constructed based on the four lncRNAs. Moreover, the four lncRNAs expression was identified by the external data in cancerous and adjacent non-cancerous tissues in CRC patients. The results demonstrated that the expression of the four lncRNAs was lower in the normal tissues than in the cancerous tissues (all p < 0.05), and the COX analysis demonstrated that the DBET, LINC00909 and FLJ33534 were assocaited with the DFS in CRC patients. The four lncRNAs were also identified in the LARC following NCRT patients, and the result demonstrated that LINC00909 and FLJ33534 had powerful ability to predict the NCRT response and prognosis (all p < 0.05). Basing on the multivariate COX analysis, we constructed a risk score and verified in the CRC and LARC patients in predicting NCRT response and prognosis. Moreover, The expression and prognosis of the DBET, LINC00909 and FLJ33534 in the CRC tissues were identified in the R2 platform and Oncomine database. Moreover, the over-expression LINC00909 cell lines demonstrated that over-expressed the LINC00909 increased the cell lines resistance to the 5-FU and radiotherapy in vivo and in vitro. Conclusion Our findings showed that DBET, LINC00909, and FLJ33534 could serve as novel biomarkers for prediction of NCRT response and prognosis in CRC patients. And LINC00909 could be a novel therapeutic targets in enhancing the NCRT response.

show abstract

“…Tumors from the brain, renal, and thyroid have repeatedly been observed to have a lower ctDNA detection compared to colorectal, lung, and breast cancer, even at an advanced stage [40,125]. Furthermore, several studies have also reported that the detection rate of ctDNA is significantly higher in colorectal cancer patients with liver metastasis compared to nodal or lung metastasis [128][129][130]. The performance of ctDNA NGS assays was found to be highly dependent on the ctDNA fraction, particularly for detecting gene amplification [42,58,131].…”

Section: Biological Limitations: Low Tumor Shedding and Non-tumoral O...mentioning

confidence: 99%

Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges

Chan

Chin

Low

2022

Cancers

View full text Add to dashboard Cite

Genomic profiling using tumor biopsies remains the standard approach for the selection of approved molecular targeted therapies. However, this is often limited by its invasiveness, feasibility, and poor sample quality. Liquid biopsies provide a less invasive approach while capturing a contemporaneous and comprehensive tumor genomic profile. Recent advancements in the detection of circulating tumor DNA (ctDNA) from plasma samples at satisfactory sensitivity, specificity, and detection concordance to tumor tissues have facilitated the approval of ctDNA-based genomic profiling to be integrated into regular clinical practice. The recent approval of both single-gene and multigene assays to detect genetic biomarkers from plasma cell-free DNA (cfDNA) as companion diagnostic tools for molecular targeted therapies has transformed the therapeutic decision-making procedure for advanced solid tumors. Despite the increasing use of cfDNA-based molecular profiling, there is an ongoing debate about a ‘plasma first’ or ‘tissue first’ approach toward genomic testing for advanced solid malignancies. Both approaches present possible advantages and disadvantages, and these factors should be carefully considered to personalize and select the most appropriate genomic assay. This review focuses on the recent advancements of cfDNA-based genomic profiling assays in advanced solid tumors while highlighting the major challenges that should be tackled to formulate evidence-based guidelines in recommending the ‘right assay for the right patient at the right time’.

show abstract

Correction: A multicentre, prospective study of plasma circulating tumour DNA test for detecting RAS mutation in patients with metastatic colorectal cancer

Abstract: An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cited by 3 publications

References 0 publications

LncRNAs Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer

LncRNAs Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer

LncRNAs Signature Associated with Chemoradiotherapy Response and Prognosis in Locally Advanced Rectal Cancer

Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges

Contact Info

Product

Resources

About